ATAI Soars 33% on Eli Lilly Acquisition

Shares of AtaiBeckley (ATAI) surged over 33% on Thursday after the company announced it would be acquired by pharmaceutical giant Eli Lilly (LLY) in a cash deal valued at up to $3.8 billion.

Under the terms, Lilly will pay $6.75 per share upfront, plus up to $2.50 per share in milestone payments tied to development and regulatory goals. The upfront price represents a roughly 26% premium over Wednesday's closing price of $5.36.

The deal is expected to close in the third quarter, pending shareholder and regulatory approvals.

AtaiBeckley is focused on developing novel treatments for mental health conditions, particularly depression. Its lead drug, BPL-003, is a synthetic psychedelic nasal spray for treatment-resistant depression that has received FDA Breakthrough Therapy Designation.

This acquisition signals Big Pharma's growing interest in psychedelic-based treatments for mental health. BPL-003 targets the biological root of depression by promoting neural connections, a different approach from traditional antidepressants.

For AtaiBeckley shareholders, the deal provides a substantial premium and a clear exit. The milestone payments could add further value if BPL-003 succeeds in Phase 3 trials and gains approval.

For Eli Lilly, the acquisition strengthens its neuroscience pipeline and positions it to address the large market of treatment-resistant depression. The deal also validates the potential of psychedelic therapies, which could spur more investment in the space.

However, risks remain: BPL-003 is still in Phase 3 trials, and regulatory approval is not guaranteed. The milestone payments are contingent on success, so the final price could be lower.